Last reviewed · How we verify
MenAfriVac™
At a glance
| Generic name | MenAfriVac™ |
|---|---|
| Also known as | Meningococcal serogroup A conjugate vaccine |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Maternal Immunization With MenAfriVac™ (PHASE3)
- Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MenAfriVac™ CI brief — competitive landscape report
- MenAfriVac™ updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI